StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Levocetirizine

HCID 1549000
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
130018-77-8
Standard-SMILES
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
InChIKey
ZKLPARSLTMPFCP-OAQYLSRUSA-N
Summenformel
C21H25ClN2O3
Durchschnittliche Molmasse
388,9 g/mol
Monoisotopische Masse
388,1553704

Überblick

2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid is a diarylmethane.

Namen und Bezeichner

Bevorzugter Name
Levocetirizine
IUPAC
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
Englischer Name
Levocetirizine
Summenformel
C21H25ClN2O3
Molmasse
388.89

Namen und Synonyme

Levocetirizine130018-77-8(R)-cetirizine(-)-CetirizineXazalCetirizine, (r)-Cetirizine, (-)-levocetrizineLevocetirizina6U5EA9RT2OAcetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
Weitere Namen anzeigen
Levocetirizine-d4(R)-2-[2-[4-(4-chlorophenyl)-phenylmethyl]-phenylmethyl-1-]-piperazinyl-]ethoxyl﹞acetic acid dihydrochloridealerlisinCetirizine-d4(R)-Cetirizine-d4Cetirizine R-Isomer
DTXSID601562942-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acidlevocetirizinum2-(2-(4-((R)-(4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid2-(2-(4-((R)-(4-chlorophenyl)-phenylmethyl)piperazin-1-yl)ethoxy)acetic acidCetirizine (r)-RefChem:55473DTXCID1078785

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,7
Polarare Oberfläche (TPSA)
53 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
8
Schwere Atome
27
Formalladung
0
Komplexität
443

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Antihistamines
Melting Point205-208

Physikochemische Eigenschaften

Schmelzpunkt
205 · 205-208°C (dec.)
Siedepunkt
542.1 · 542.1±45.0 °C(Predicted)
Dichte
1.237 · 1.237±0.06 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
Löslichkeit
78 mg/mL · DMSO: 78 mg/mL (200.57 mM);Ethanol: 78 mg/mL (200.57 mM)
pka
3.46 · 3.46±0.10(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white
Wasserlöslichkeit
78 mg/mL · Water: 78 mg/mL (200.57 mM)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Levocetirizine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

hs_code
29335990

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

R06AE09

R - Respiratory system

QR - Respiratory system

Protein BindingPlasma protein binding of levocetirizine was on average 96.1% 1 hour post dose and 91.9% 6 hours post dose.
Pharmacodynamics · 1 Eintrag

Levocetirizine is a second generation histamine H<sub>1</sub> antagonist used to treat various allergic symptoms. It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose. Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.

Mechanism of Action · 1 Eintrag

Levocetirizine selectively inhibits histamine H<sub>1</sub> receptors. This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.

Biological Half-LifeThe average half life of levocetirizine is 7.05±1.54 hours.
Metabolism/Metabolites · 1 Eintrag

Levocetirizine is poorly metabolized with 85.8% of an oral dose being excreted as the unchanged drug. Levocetirizine can be metabolized to a dihydrodiol (M2), an N-oxide (M3), a hydroxymethoxy derivative (M4), a hydroxy derivative (M5), an O-dealkylated derivative (M6), a taurine conjugate (M8), and an N-dealkylated and aromatic hydroxylated derivative (M9). The M5 metabolite can be glucuronidated to form the M1 metabolite and the M9 metabolite can form 4-chloro-4'-hydroxybenzhydryl mercapturates (M10a and M10b).

FDA Pharmacological Classification · 5 Einträge

6U5EA9RT2O

LEVOCETIRIZINE

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 661320
HRID 661320als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
130018-77-8
PubChem CID
1549000
DTXSID
DTXSID60156294
ChEMBL
CHEMBL1201191
ChEBI
CHEBI:94559
UNII
6U5EA9RT2O
Nikkaji
J1.370.778B
BCS Class
3 · 3
CAS Datenbank
130018 · 130018-77-8(CAS DataBase Reference)

Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists

Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist

Levocetirizine is a Histamine-1 Receptor Antagonist. The mechanism of action of levocetirizine is as a Histamine H1 Receptor Antagonist.

MeSH Pharmacological Classification · 1 Eintrag

A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.

Absorption, Distribution and Excretion · 4 Einträge

Following a 5mg oral dose of levocetirizine, a Cmax of 0.27±0.04µg/mL with a Tmax of 0.75±0.50h. The AUC of levocetirizine is 2.31±0.50µg\*h/mL. Taking levocetirizine with food does not affect the AUC but delays Tmax by 1.25 hours and lowers Cmax by 36%.

168 hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces. In the urine, 77% of the dose was recovered as unchanged drug, 0.5% as the M8 and M9 metabolites, 0.4% as the M10a metabolite, 0.4% as the M10b metabolite, 0.3% as the M3 metabolite, 0.3% as the M4 and M5 metabolite, 0.2% as the M2 metabolite, and 0.1% as the M1 metabolite. In the feces, 9.0% of the dose was recovered as unchanged drug, 1.0% as the M4 and M5 metabolite, and 0.1% as the M1 metabolite.

The volume of distribution of levocetirizine is 0.33±0.02L/kg.

The average clearance of levocetirizine is 0.57±0.18mL/min/kg.

Metabolite PathwaysLevocetirizine H1-Antihistamine Action

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >100
Use ClassificationPharmaceuticals -> Antihistamines
Anwendungen · 2 Einträge

BeschreibungThe (R)-enantiomer of the second-generation antihistamine cetirizine, levocetirizine, was first introduced in Germany for seasonal allergic rhinitis (including ocular symptoms), perennial allergic rhinitis and chronic idiopathic urticaria. The dihydrochloride salt can be prepared in four steps from optically active 4-chlorobenzhydrylamine obtained by resolution of its racemate with (+)-tartaric acid. Levocetirizine (eutomer) is a 2-fold more potent H1 antagonist than cetirizine whereas the other enantiomer (distomer) is 10-fold less potent compared to levocetirizine. Pharmacodynamic studies on healthy volunteers showed that compared to cetirizine, half the dose of levocetirizine (5 mg) was necessary to obtain similar inhibitory effects in the skin test of histamine-induced wheal and flare as well as on histamine-induced nasal congestion and nasal resistance. There was no evidence of chiral inversion of levocetirizine in vivo in several species including human. The daily dose of drug is rapidly and extensively absorbed in human. Interestingly, its volume of distribution (0.41 kg/L) is smaller than that of the distomer (0.60 kg/L). The low volume of distribution is considered as favorable for an antihistamine both in terms of efficacy and safety. Due to its high metabolic stability and lack of effect on the activities of the major CYP isoenzymes, levocetirizine is unlikely to cause interactions with other administered drugs. No clinically relevant effect on electrocardiograms of healthy volunteers was detected.

VerwendenA nonsedating type histamine H1-receptor antagonist. A major metabolite of Hydroxyzine. Pharmacological activity resides primarily in the (R)-isomer. Antihystaminic.